CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多发性骨髓瘤治疗后的继发性肿瘤
英文原题：Secondary neoplasms following treatment for multiple myeloma.
查看英文原题
Secondary neoplasms following treatment for multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）是一种血液系统恶性肿瘤，其特征为骨髓内浆细胞的克隆性增殖，导致显著的终末器官损害。近期的治疗进展，包括免疫调节药物（IMiDs）、蛋白酶体抑制剂、自体干细胞移植（ASCT）和CAR-T 细胞疗法，已显著改善了生存结局。然而，随着生存期的延长，治疗相关的继发性恶性肿瘤（SM），特别是治疗相关的髓系肿瘤（tMN）和继发性淋巴系肿瘤，日益引起关注。本文综述了MM患者继发性恶性肿瘤的发病率、相关因素、临床病理特征及结局，包括近期关于治疗相关B淋巴母细胞白血病和淋巴瘤的观察结果。
展开英文摘要原文
Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells within the bone marrow, leading to significant end-organ damage. Recent therapeutic advancements, including immunomodulatory drugs (IMiDs), proteasome inhibitors, autologous stem cell transplant (ASCT), and chimeric antigen receptor T-cell (CAR-T) therapy, have significantly improved survival outcomes.
However, with prolonged survival, there is an emerging concern regarding therapy-related secondary malignancies (SM), particularly therapy-related myeloid neoplasms (tMN) and secondary lymphoid neoplasms. This article reviews the incidence, contributing factors, clinicopathological features, and outcomes associated with secondary malignancies in MM patients, including recent observations on therapy-related B-lymphoblastic leukemia and lymphomas.
论文信息
- 作者
- Germans SK、Zhang B、Weinberg O
- 第一作者单位
- Assistant professor, Department of Hematopathology, University of Texas Southwestern, Dallas, TX, USA. Electronic address: sharon.germans@UTSouthwestern.edu.United States
- 通讯作者单位
- Professor, Department of Hematopathology, University of Texas Southwestern, Dallas, TX, USA. Electronic address: olga.weinberg@UTSouthwestern.edu.United States
- 文献类型
- 综述
- 期刊
- Seminars in diagnostic pathology2026 Jan
- 原文标识
- PubMed 41343974 · DOI 10.1016/j.semdp.2025.150976